CapsoVision Stock On Fire: Up 114% With 6-Day Winning Streak
CapsoVision (CV) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 114% return. The company has gained about $119 Mil in value over the last 6 days, with its current market capitalization at about $224 Mil. The stock remains 66.5% below its value at the end of 2024. This compares with year-to-date returns of 17.1% for the S&P 500.
CapsoVision’s recent streak stems from its FDA Breakthrough Device Designation for pancreatic cancer screening, a significant catalyst for accelerated development. This momentum is further bolstered by strong Q3 revenue growth and expanding CapsoCam Plus adoption, alongside strategic advancements in AI-enabled capsule endoscopy and a recent investor conference.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.For quick background, CV provides advanced imaging and AI technologies in capsule endoscopy solutions to detect gastrointestinal tract abnormalities for diagnostic and screening purposes.
Comparing CV Stock Returns With The S&P 500
- The Next Big Rally in Ford Motor Stock Could Start Like This
- The Risk Factors to Watch Out For in NVIDIA Stock
- Intuitive Surgical Stock Now 16% Cheaper, Time To Buy
- AT&T Stock Pays Out $85 Bil – Investors Take Note
- Intel Stock Pays Out $92 Bil – Investors Take Note
- Comcast Stock Capital Return Hits $44 Bil
The following table summarizes the return for CV stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | CV | S&P 500 |
|---|---|---|
| 1D | 32.7% | 0.7% |
| 6D (Current Streak) | 113.8% | 0.8% |
| 1M (21D) | 138.9% | 0.8% |
| 3M (63D) | 218.9% | 4.5% |
| YTD 2025 | -66.5% | 17.1% |
| 2024 | 0.0% | 23.3% |
| 2023 | 0.0% | 24.2% |
| 2022 | 0.0% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 61 S&P constituents with 3 days or more of consecutive gains and 45 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 18 | 22 |
| 4D | 13 | 10 |
| 5D | 2 | 2 |
| 6D | 12 | 4 |
| 7D or more | 16 | 7 |
| Total >=3 D | 61 | 45 |
Key Financials for CapsoVision (CV)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $9.8 Mil | $11.8 Mil |
| Operating Income | $-11.3 Mil | $-19.9 Mil |
| Net Income | $-11.3 Mil | $-19.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $3.3 Mil | $3.5 Mil |
| Operating Income | $-4.7 Mil | $-8.0 Mil |
| Net Income | $-4.6 Mil | $-7.9 Mil |
While CV stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.